Patients with acute lung injuries are being widely reported due to numerous factors, such as the increasing aged population and the rising number of patients with sepsis and pneumonia. However, most people get diagnosed with lung injuries and acute respiratory distress syndrome only at the late stages. The disease is a rapidly progressive condition occurring in patients with damaged lungs, causing bodily fluids to leak. The number of acute respiratory distress syndrome cases and lung injuries is increasing due to the emergence of various respiratory illness-causing viruses in recent years.
Thereby, the incidence and prevalence of ARDS keep increasing, and the disease has been widely recognized as a major clinical problem worldwide, carrying a high morbidity and mortality burden. Hence, increasing prevalence and incidence rates of acute lung injuries and accompanying acute respiratory distress syndrome are expected to drive market growth.
Access Full Report @ https://www.databridgemarketresearch.com/zh/reports/global-acute-respiratory-distress-syndrome-ards-treatment-market
Data Bridge Market Research analyzes the Global Acute Respiratory Distress Syndrome (ARDS) Treatment Market is expected to reach USD 9,954,720.47 thousand by 2030 from USD 4,577,440.16 thousand in 2022, growing with a substantial CAGR of 10.6% in the forecast period of 2023 to 2030.
Key Findings of the Study
Wide Range of Risk Factors for ARDS Treatment
An enormous range of risk factors is being reported for acute respiratory distress syndrome. There are environmental and individual risk factors involved with the syndrome. Some chronic alcohol consumption and active or passive cigarette smoking have been commonly associated. As of July 2015, the National Center for Biotechnology Information (NCBI) published an article titled "Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)," which stated that vitamin D deficiency is commonly seen in people developing ARDS, thereby contributing to the development of the condition as a risk factor.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Thousand, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause (Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Gilead Sciences Inc.(U.S.), Terumo Corporation (Japan), Getinge (Sweden), LivaNova PLC (U.K.), Medtronic (Ireland), WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany), Besmed Health Business Corp. (Taiwan), ResMed (U.S.), Drägerwerk AG & Co. KGaA (Germany), Fisher & Paykel Healthcare Limited (New Zealand), Armstrong Medical (Northern Ireland), Fresenius SE & Co. KGaA. (Germany), NIPRO (Japan), Pfizer Inc. (U.S.), Hamilton Medical. (Switzerland), nice Neotech Medical Systems Pvt. Ltd. (India), and EUROSETS (Italy), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global acute respiratory distress syndrome (ARDS) treatment market is segmented into five notable segments on the basis of type, cause, route of administration, end user, and distribution channel.
- On the basis of type, the market is segmented into mechanical ventilation, corticosteroids, antiviral medication, extracorporeal membrane oxygenation (ECMO), tocilizumab, and others.
In 2023, the mechanical ventilation segment is expected to dominate the global acute respiratory distress syndrome (ARDS) treatment market.
In 2023, the mechanical ventilation segment is expected to dominate the market with 38.60% market share as it plays a significant role in improving patient outcomes by maintaining adequate oxygenation and ventilation in patients with ARDS.
- On the basis of cause, the market is segmented into sepsis, inhalation of harmful substances, severe pneumonia, and others.
In 2023, the sepsis segment is expected to dominate the global acute respiratory distress syndrome (ARDS) treatment market.
In 2023, the sepsis segment is expected to dominate the market with 52.25% market share as it is recognized as a major contributor to the development of ARDS. Therefore, a severe infection leads to a dysregulated immune response, systemic inflammation, and organ dysfunction, including the lungs.
- On the basis of route of administration, the market is segmented into parenteral, oral, and others. In 2023, parenteral segment is expected to dominate with a market share of 66.37%.
- On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others. In 2023, hospitals segment is expected to dominate with a market share of 63.12%.
- On the basis of distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, and online pharmacy. In 2023, the direct tender segment is expected to dominate with a market share of 46.18%.
Major Players
Data Bridge Market Research analyzes Gilead Sciences Inc. (U.S.), Terumo Corporation (Japan), Getinge (Sweden), LivaNova PLC (U.K.), and Medtronic (Ireland) as the major market players in the global acute respiratory distress syndrome (ARDS) treatment market.
Market Developments
- In July 2023, ResMed announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software. This acquisition helps the organization develop more revenue.
- In October 2022, NIPRO announced that one of its consolidated subsidiaries, Nipro Asia Pte. Ltd., had established a medical device sales subsidiary—Nipro Medical Philippines Corp., in the Republic of the Philippines. This helped the organization develop more revenue.
- In November 2021, Fisher & Paykel Healthcare Limited announced the launch of F&P Visairo Hospital under-nose mask for noninvasive ventilation. F&P Visairo is a new high-performance under-nose hospital mask with dynamic support technology. This allows for bridge-free, noninvasive ventilation, which eliminates pressure from the bridge of the nose and clears the way for an open field of vision without compromising on stability and performance. This helped the company to expand its product portfolio.
- In April 2021, Hamilton Medical announced that they had launched new HAMILTON-C1/T1/MR1 ventilators with various features, including CPR ventilation, upgraded high-flow oxygen therapy, volume Support mode, and digital solutions for respiratory care. This helped the company to increase its global presence in the market and raise their revenues.
- In February 2021, Pfizer CentreOne announced the new campaign of API & Intermediates. This campaign focused on a comprehensive range of complex API compounds and intermediates for drug product developers and manufacturers. This campaign launch helped the company to reach the market.
Regional Analysis
On the basis of geography, the market is segmented into U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is the dominant region in the global acute respiratory distress syndrome (ARDS) treatment market
North America is expected to dominate the market due to the rising prevalence of acute lung injury among the population in this region.
Asia-Pacific is estimated to be the fastest-growing region in the global acute respiratory distress syndrome (ARDS) treatment market.
Asia-Pacific is expected to be the fastest-growing region in the market due to rising healthcare expenditure to improve treatment facilities.
For more detailed information about the global acute respiratory distress syndrome (ARDS) treatment market report, click here – https://www.databridgemarketresearch.com/zh/reports/global-acute-respiratory-distress-syndrome-ards-treatment-market
